## Remarks

The present Preliminary Amendment cancels claims 1-49 and 70-81, and adds claims 82-106, all of which are drawn to vectors and methods of use thereof. Applicants submit that the new claims are properly included in Group III, which was elected in the Response to Restriction Requirement filed December 15, 2005. Support for new claims 82-106 is found throughout the specification, e.g., in the Abstract, in the original claims, at paragraphs 42- 48 (p. 10, line 18 – p. 13, line 10), which discuss vectors that lack one or more components needed for systemic movement or cell-to-cell movement, vectors that contain a gene that encodes a replicase protein, vectors that include a polynucleotide of interest, etc., and at paragraph 60 (p. 17, lines 15-19), which discuss production of multimeric proteins.

Applicants thank the Examiner for careful consideration of this case. Should any questions arise in connection with this Preliminary Amendment, the Examiner is invited to telephone the undersigned at the phone number listed below.

It is believed that no fee is due in association with this Preliminary Amendment. However, if there are any fees associated with this matter, please charge them to our Deposit Account No. 03-1721.

Respectfully submitted,

Monica R. Gerber, M.D., Ph.D. Registration Number 46,724

Dated: December 21, 2005

Choate, Hall & Stewart, LLP Two International Place Boston, MA 02110

Tel: (617) 248-5000 (x-5071)